Content Conference Coverage Conferences
Previous Conferences
- Details
- Category: Conferences
- Created on Saturday, 25 February 2012 12:27
The Liver Meeting (AASLD 2014)
November 7-11, 2014, Boston
HIV Drug Therapy 2014
November 2-6, 2014, Glasgow
HIV Research for Prevention (HIVR4P 2014)
October 28-31, 2014, Cape Town
IDWeek 2014
October 8-12, 2014, Philadelphia
54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014)
September 5-9, 2014, Washington, DC
20th International AIDS Conference (AIDS 2014)
July 20-25, 2014, Melbourne
Digestive Disease Week 2014
May 3-6, 2014, Chicago
49th International Liver Congress (EASL 2014)
April 9-13, 2014, London
2014 Conference on Retroviruses and Opportunistic Infections (CROI 2014)
March 3-6, 2014, Boston
The Liver Meeting (AASLD 2013)
November 1-5, 2013, Washington, DC
14th European AIDS Conference (EACS 2013)
October 16-19, 2013, Brussels
IDWeek 2013
October 2-6, 2013, San Francisco
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013)
September 10-13, 2013, Denver
7th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2013)
June 30-July 3, 2013, Kuala Lumpur
Digestive Disease Week 2013
May 18-21, 2013, Orlando
48th International Liver Congress (EASL 2013)
April 24-28, 2013, Amsterdam
20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)
March 3-6, 2013, Atlanta
11th International Congress on Drug Therapy in HIV Infection (HIV11)
November 11-15, 2012, Glasgow
The Liver Meeting (AASLD 2012)
November 9-13, 2012, Boston
52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)
September 9-12, 2012, San Francisco
XIX International AIDS Conference (AIDS 2012)
July 22-27, 2012, Washington, DC
19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
March 5-8, 2012, Seattle
The Liver Meeting (AASLD 2011)
November 4-8, 2011, San Francisco
49th Annual Meeting of the Infectious Disease Society of America (IDSA 2011)
October 20-23, 2011, Boston
13th European AIDS Conference (EACS 2011)
October 12-15, 2011, Belgrade
51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011)
September 17-20, 2011, Chicago
6th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2011)
July 17-20, 2011, Rome
46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011)
March 30-April 3, 2011, Berlin
18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
February 27-March 2, 2011, Boston
The Liver Meeting (AASLD 2010)
October 29-November 3, 2010, Boston
50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010)
September 12-15, 2010, Boston
XVIII International AIDS Conference (AIDS 2010)
July 18-23, 2010, Vienna
AASLD 2006: Liver Transplantation in HIV Positive Patients
- Details
- Category: 2006 Conferences
- Created on Saturday, 04 November 2006 00:00
The Thomas E. Starzl Transplant Surgery State-of the-Art Lecture at this year’s American Association for the Study of Liver Diseases (AASLD) annual meeting was devoted to the outcomes following solid organ transplantation in HIV-infected recipients. The speaker, Peter G. Stock, MD, from the University of California at San Francisco, gave a very good update on the topic.
18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
- Details
- Category: CROI 2011
- Created on Saturday, 09 July 2011 10:45
HIV/AIDS Articles
- Can Lowering Community Viral Load Decrease New HIV Infections?
- Positive Pulse: Expert Commentaries From CROI 2011*
- HPV and Anal Cancer Research at CROI 2011
- HIV Enters and Injures Brain Early
- Vitamin D May Reduce Tenofovir-related Bone Loss
- Do Black Patients Respond Less Well to Antiretroviral Therapy?
- Immediate ART Improves Survival for HIV+ People with TB
- Reduced Limb Muscle, More Belly Fat Linked to Higher Mortality
- Studies Shed Further Light on Cardiovascular Disease among People with HIV
- Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
- Longer Preventive Therapy, More Drugs Reduce Risk of Mother-to-Child HIV Transmission
- Experimental Integrase Inhibitor Dolutegravir Looks Promising for People with Resistant HIV
- Is Bone Loss Related to Immune Reconstitution in People on ART?
- New Tenofovir Pro-drug GS-7340 Looks Good in Early Study
- 5 Drugs No Better than 3 for Treatment of Primary HIV Infection
- Long-term Benefits of Circumcision for HIV Prevention
- No More Science Fiction -- HIV Gene Therapy Delivers
- Once-daily Raltegravir Found Less Effective than Twice-Daily Dosing
- HIV Attachment Inhibitor BMS-663068 Shows Good Activity in Phase 2a Trial
- Researchers Report Further Findings from iPrEx PrEP Trial
- Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
- FDA Safety Review Does Not Find Abacavir-Heart Attack Link
- International AIDS Society Launches International HIV Cure Working Group
HIV/HCV and HIV/HBV Coinfection Articles
- HCV Re-infection Common among HIV+ Gay Men in Amsterdam
- HIV/HCV Coinfected People Have Higher Risk of Bone Loss
- Acute Hepatitis C Treatment for HIV/HCV Coinfected People
- Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir
- Liver Fibrosis Raises Risk of Kidney Impairment in HIV/HBV Coinfected Patients on Tenofovir
- Little Overlap of Sexually Transmitted HCV between U.S. and Europe
- More Liver-related Death for HIV/HBV than HIV/HCV Coinfection in MACS Cohort
- Telaprevir Improves Treatment Outcomes for HIV/HCV Coinfected People
Library of Slides and Posters
-
Success of Test and Treat in San Francisco? Reduced Time to VirologicSuppression, Decreased Community Viral Load, and Fewer New HIV Infections, 2004 to 2009
M Das and others. CROI 2011. -
Use of Community Viral Load as Population-Based Biomarker of HIV „Ÿ Washington, DC, 2004 . 2008
A Castel and others. CROI 2011. -
Disparities in Community Viral Load among HIV Infected Persons in NYC
F Laraque and others. CROI 2011. -
HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors
M Freiberg and others. CROI 2011. -
Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members
D Klein and others. CROI 2011. -
No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis
X Ding and others. CROI 2011. -
Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years Treatment (Tx): 156 Week (Wk) Results from STARTMRK
J Rockstroh and others. CROI 2011. -
ARIEL: 24-week safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years
A Violari and others. CROI 2011. -
Pharmacokinetic Parameters of Once-Daily TMC278 Following Administration of Efavirenz in Healthy Volunteers
H Crauwels and others. CROI 2011. -
Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 data from the randomized, double-blind, Phase III ECHO and THRIVE trials
J Arribas and others. CROI 2011. -
Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks
A Mills and others. CROI 2011. -
Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial
D Wohl and others. CROI 2011. -
GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir DisoproxilFumarateDuring 14 Days of Monotherapyin HIV-1 Infected Subjects
A Diamond and others. CROI 2011. -
No Association of Myocardial Infarction with ABC Use: An FDA Meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections
X Ding and others. CROI 2011.
CROI 2007: Another Report of Drug-resistant HIV in a Patient Treated with Entecavir (Baraclude) for Hepatitis B
- Details
- Category: 2007 Conferences
- Created on Friday, 11 April 2008 13:42
At the 14th Conference on Retroviruses and Opportunistic Infections (CROI) in February 2007, researchers reported that the hepatitis B drug entecavir (Baraclude) is also active against HIV, and can select for the M184V mutation that confers resistance to the antiretroviral drugs lamivudine (3TC; Epivir) and emtricitabine (Emtriva).
Coverage of the 46th Annual Meeting of the European Association for the Study of the Liver
- Details
- Category: EASL 2011
- Created on Tuesday, 05 July 2011 21:51
March 30 - April 3, 2011, Berlin, Germany
The material posted on HIVandHepatitis.com is not approved by nor is it a part of EASL 2011.
Hepatitis C Articles
- EASL Releases New Hepatitis C Clinical Practice Guidelines
- Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
- Tegobuvir Works Well in Triple and Quad Regimens for HCV
- Boosted Danoprevir Improves Response in Prior Null Responders
- Once-Daily BI201335 Ups Response to Interferon for Hepatitis C
- BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
- Statin Boosts Response to Pegylated Interferon/Ribavirin
- Boceprevir Helps Hepatitis C Patients with Cirrhosis
- TMC435 Beats Standard Therapy Regardless of HCV Genotype
- Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
- Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- Pegylated Interferon Lambda Boosts Response with Few Side Effects
- First Sustained Response Data for Polymerase Inhibitor Mericitabine
- 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
- Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
- BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
- Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab
Hepatitis B Articles
- Kidney Toxicity Uncommon among People Taking Tenofovir for Hepatitis B
- HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
- Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
Library of Slides and Posters
-
Baseline Genotype And HBsAg Were Found To Have Signifi cant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment
J Heathcote and others. EASL 2011. -
Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist
D Tumas and others. EASL 2011. -
Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
R Lanford and others. EASL 2011. -
Anti-Viral Effi cacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection
S Menne and others. EASL 2011. -
Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon a-2a and Ribavirin in the PILLAR Study
J Aerssens and others. EASL 2011. -
Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin
O Lenz and others. EASL 2011. -
Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment
V Sekar and others. EASL 2011. -
The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis
S Zeuzem and others. EASL 2011. -
First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects
S Pol and others. EASL 2011. -
A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
E Lawitz and others. EASL 2011. -
Interim Results of a Randomized Treatment Study of Emtricitabine/Tenofovir DF (FTC/TDF) and HBIG Withdrawal in Post-Orthotopic Liver Transplant (OLT) Recipients for CHB
L Tepperman and others. EASL 2011. -
Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451
A Corsa and others. EASL 2011. -
Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB)
S Fung and others. EASL 2011. -
Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies
P Marcellin and others. EASL 2011. -
A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects
U Lopatin and others. EASL 2011. -
HBsAg Kinetics in Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumurate (TDF) for up to 4 years
P Marcellin and others. EASL 2011.
More Articles...
- HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
- IAS 2011: Inflammation Markers Linked to Liver Disease, Death in HIV/HBV and HIV/HCV Coinfection
- EASL 2012: Boceprevir Improves Cure Rates for HIV/HCV Coinfection but Beware of Drug Interactions
- AIDS 2012 Conference Program Now Online, Global Village Events Free
- International AIDS Society WiIll Host International AIDS Conference in U.S. after a 22-year Absence
- IAS 2013: Adolescents with HIV Face Challenges Transitioning to Adulthood [VIDEO]
- 14. HIV Researchers and Advocates Killed in Plane Crash En Route to AIDS Conference
- HR17: Overamping Is a Common Problem Among People Who Use Stimulants
Subcategories
- 2004 Conferences
- 2005 Conferences
- 2006 Conferences
- 2007 Conferences
- CROI 2008
- AIDS 2008
- ICAAC 2008
- AASLD 2008
- HIV9 (2008)
- CROI 2009
- EASL 2009
- IAS 2009
- ICAAC 2009
- AASLD 2009
- CROI 2010
- EASL 2010
- AIDS 2010
- ICAAC 2010
- AASLD 2010
- HIV10 (2010)
- CROI 2011
- EASL 2011
- IAS 2011
- ICAAC 2011
- EACS 2011
- IDSA 2011
- AASLD 2011
- CROI 2012
- EASL 2012
- AIDS 2012
- ICAAC 2012
- AASLD 2012
- HIV11 (2012)
- DDW 2009
- DDW 2008
- EASL 2008
- CROI 2013
- EASL 2013
- DDW 2013
- IAS 2013
- USCA 2013
- ICAAC 2013
- AASLD 2013
- CROI 2014
- EASL 2014
- DDW 2014
- AIDS 2014
- ICAAC 2014
- USCA 2014
- IDWeek 2014
- HIV R4P 2014
- HIV Drug Therapy 2014
- AASLD 2014
- CROI 2015
- EASL 2015
- BHIVA 2015
- DDW 2015
- IAS 2015
- ICAAC 2015
- IDWeek 2015
- INHSU 2015
- IHRC 2015
- EACS 2015
- AASLD 2015
- NHPC 2015
- WCLH 2015
- EASL 2016
- AIDS 2016
- AASLD 2016
- CROI 2016
- BHIVA 2016
- DDW 2016
- ASM Microbe 2016
- INHSU 2016
- HIV Drug Therapy 2016
- HIV R4P 2016
- IDWeek 2016
- HIV PrEP Summit 2016
- USCA 2016
- 2016 STD Prevention
- CROI2017
- AASLD2017
- EASL2017
- HR17
- PAS17
- IAS 2017
- IDWeek 2017
- EACS 2017
Web Design and Development by